Alzheimer’s

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a common neuropsychiatric symptom in Alzheimer’s dementia and one of the most […]

Rivka Kreitman, CIO of NeuraLight explores the landscape of therapies for Alzheimer’s and explains why digital biomarkers are key to combatting the disease. Neurodegenerative diseases – the collection of progressive conditions characterised by neuron cell damage and death and subsequent loss of motor function – represent a significant burden for patients, their caregivers, and the […]

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.  Context   Researchers at Washington University School of Medicine in St Louis showed that the tens of trillions of microbes that normally live in […]

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage […]

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories:  Experimental immunotherapy has over 70% response rate  An immunotherapy that uses a new […]

A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases.  The Proceedings of the National Academy of Sciences (PNAS) will publish results of the groundbreaking study demonstrating a customised, synthetic peptide’s ability to selectively detect Alzheimer’s disease.  The approach […]

Scientists have found a new drug treatment that can slow the progression of neurodegenerative disease in mice. The breakthrough research may offer fresh hope in tackling currently untreatable conditions such as Alzheimer’s disease (AD).  The study was led by researchers at the University of Glasgow’s new Advanced Research Centre (ARC) and published in Science Signaling. […]

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ team was led by Professor Trent Woodruff and Dr Eduardo […]

Early-cognitive decline may result from a shift in the ratio of a protein sub-type in our brain cells triggering cell-loss, according to a new study. The discovery, published in Scientific Reports, provides a new therapeutic target to prevent the onset of neurodegenerative diseases including dementia and Alzheimer’s. It is the first study to examine the […]